Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DiagnoCure and Genzyme seal lung cancer test pact

This article was originally published in Clinica

Executive Summary

In a bid to optimise its investigational molecular test for lung cancer, DiagnoCure has licensed from Genzyme worldwide exclusive rights to around 40 genes for potential use in detecting the disease. The genes are intended to supplement those in the original version of DiagnoCure's assay - which uses bronchial aspirate samples - and may also be used to develop new tests that employ other sample types such as blood, sputum, or biopsy materials.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT056936

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel